An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children’s Oncology Group Study ACNS0331)

Schiff JP, Lee Y, Wang Y, Perkins SM, Kessel SK, Fitzgerald TJ, Larrier NA, Michalski JM. An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children’s Oncology Group Study ACNS0331). Adv Radiat Oncol. 2023 Jan-Feb;8(1):101083. doi: 10.1016/j.adro.2022.101083. eCollection 2023 Jan-Feb. PubMed PMID: 36483060; PubMed Central PMCID: PMC9723303.

Craniospinal irradiation remains an essential and yet difficult part of the treatment of patients with medulloblastoma. Whereas technological advances offer promise of increased conformity, realiance on advanced technology is not without risk, and it remains critical to carefully delineate targets. We describe examples of target deviations (TDs) in craniospinal irradiation treatment plans for postoperative patients with medulloblastoma in a phase 3 clinical trial (ACNS 0331).